Abstract:BACKGROUND:The immunosuppressive tumor microenvironment (TME) is a key characteristic of human cancer. Immunotherapy has emerged as a promising treatment strategy to overcome immune escape and has gained widespread use in recent years. In particular, the blockade of PD-1/PD-L1 interaction holds significant importance in oncotherapy. Combining anti-PD-1/PD-L1 with small molecule inhibitors targeting key pathways represents an emerging trend in therapeutic development. METHODS:To validate our findings biologically, we employed qRT-PCR or Western blotting and immunofluorescence staining techniques to assess the expression levels of DIAPH1 and PD-L1 in cells. Additionally, CCK8 and clone formation assays were utilized to evaluate cell proliferation ability, while flow assays were conducted to detect apoptosis in T cells. RESULTS:Knockdown of DIAPH1 restored the tumor-killing capacity of T cells, effectively suppressing tumor immune escape. We observed a highly positive correlation between the expression levels of DIAPH1 and 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), which can be competitively inhibited by lovastatin. Through Sybyl analysis followed by confirmation via micro scale thermophoresis, we identified lovastatin as a potential inhibitor targeting DIAPH1. Lovastatin downregulated DIAPH1 expression both in tumor cell lines and xenograft lung cancer tissues within a mouse lung cancer model. Furthermore, we found that lovastatin degraded DIAPH1 through lysosomal degradation pathway. Treatment with lovastatin was strongly associated with improved response rates and prolonged overall survival among patients with lung adenocarcinoma. Finally, overexpression of DIAPH1 reversed the inhibitory effects mediated by lovastatin on tumor development. CONCLUSIONS:Lovastatin downregulates PD-L1 expression by targeting DIAPH1 and restores the tumor-killing ability of T cells to block tumor immune escape. Lovastatin may become a potential drug for cancer patients to enhance immunotherapy response in the clinic.

The mechanism of lovastatin in suppressing the proliferation of esophageal squamous cell carcinoma based on proteomics

Proteome and phosphoproteome reveal mechanisms of action of atorvastatin against esophageal squamous cell carcinoma

Proteomic Analysis of the Molecular Mechanism of Lovastatin Inhibiting the Growth of Nasopharyngeal Carcinoma Cells.

Ott_a_237693 2057..2066

Mevalonate Pathway is a Therapeutic Target in Esophageal Squamous Cell Carcinoma

Cloperastine inhibits esophageal squamous cell carcinoma proliferation in vivo and in vitro by suppressing mitochondrial oxidative phosphorylation

Proteomics Reveal the Inhibitory Mechanism of Levodopa Against Esophageal Squamous Cell Carcinoma

Simvastatin Inhibits the Malignant Behaviors of Gastric Cancer Cells by Simultaneously Suppressing YAP and β-Catenin Signaling.

Lovastatin suppresses bacterial therapy-induced neutrophil recruitment to the tumor by promoting neutrophil apoptosis

Lovastatin-mediated Pharmacological Inhibition of Formin Protein DIAPH1 Suppresses Tumor Immune Escape and Boosts Immunotherapy Response

Lovastatin Inhibits Cell Proliferation and Migration in Cholangiocarcinoma Cell Line QBC939

An Overview On The Biological Activity And Anti-Cancer Mechanism Of Lovastatin

The anti-tumor effects of dual PI3K/mTOR inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A on inducing autophagy in esophageal squamous cell carcinoma

Hexokinase 2 is a Pivot for Lovastatin-induced Glycolysis-to-Autophagy Reprogramming in Triple-Negative Breast Cancer Cells

Integrin β3 and LKB1 are independently involved in the inhibition of proliferation by lovastatin in human intrahepatic cholangiocarcinoma.

Simvastatin Inhibits Renal Cancer Cell Growth and Metastasis Via AKT/mTOR, ERK and JAK2/STAT3 Pathway

BRCA1 Overexpression Sensitizes Cancer Cells to Lovastatin Via Regulation of Cyclin D1-CDK4-p21WAF1/CIP1 Pathway: Analyses Using a Breast Cancer Cell Line and Tumoral Xenograft Model

Dysregulated Ribosome Biogenesis is a Targetable Vulnerability in Triple-Negative Breast Cancer: MRPS27 As a Key Mediator of the Stemness-inhibitory Effect of Lovastatin

Simvastatin Inhibits Proliferation and Promotes Apoptosis of Oral Squamous Cell Carcinoma Through KLF2 Signal.

Lovastatin/SN38 Co-Loaded Liposomes Amplified ICB Therapeutic Effect Via Remodeling the Immunologically-Cold Colon Tumor and Synergized Stimulation of Cgas-Sting Pathway.

Lovastatin Induces Apoptosis of HepG-2 Cells by Activating ROS-dependent Mitochondrial and ER Stress Pathways.